Bjørn Allan Moum
- Professor, Consultant of Gastroenterology; MD, PhD
- +47 450 65 275
Education:
- MD University of Århus Denmark 1980
- Dr med University of Oslo (1997)
- Norwegian clinical specialist accreditations
Internal medicine and gastroenterology (1991)
Current position:
- Professor University of Oslo
- Consultant, Department of gastroenterology, Oslo University Hospital
Publications 2021
First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study
Scand. J. Gastroenterol., 56 (10), 1163-1168
DOI 10.1080/00365521.2021.1955147
Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact
World J. Gastroenterol., 27 (17), 2039-2053
DOI 10.3748/wjg.v27.i17.2039
Incidence and Prevalence of Inflammatory Bowel Disease in Norway and the Impact of Different Case Definitions: A Nationwide Registry Study
Clin. Epidemiol., 13, 287-294
DOI 10.2147/CLEP.S303797
Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study
J. Crohns Colitis, 15 (6), 969-979
DOI 10.1093/ecco-jcc/jjaa232
Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic
Scand. J. Gastroenterol., 56 (5), 545-551
DOI 10.1080/00365521.2021.1901308
Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease
JHEP Rep., 3 (1), 100178
DOI 10.1016/j.jhepr.2020.100178
Publications 2020
Pain Severity and Vitamin D Deficiency in IBD Patients
Nutrients, 12 (1), 26
DOI 10.3390/nu12010026
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis
Clin. Gastroenterol. Hepatol., 18 (10), 2295-+
DOI 10.1016/j.cgh.2020.02.014
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
Biodrugs, 34 (5), 681-694
DOI 10.1007/s40259-020-00438-7
Risk of colorectal cancer in a population-based study 20 years after diagnosis of ulcerative colitis: results from the IBSEN study
BMJ Open Gastroenterol., 7 (1), e000361
DOI 10.1136/bmjgast-2019-000361
Association of Childbearing With a Short-Term Reduced Risk of Crohn Disease in Mothers
Am. J. Epidemiol., 189 (4), 294-304
DOI 10.1093/aje/kwz285
Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients - the IBSEN study
Scand. J. Gastroenterol., 55 (4), 436-441
DOI 10.1080/00365521.2020.1745879
Self-esteem in patients with inflammatory bowel disease
Qual. Life Res., 29 (7), 1839-1846
DOI 10.1007/s11136-020-02467-9
The Impact of Spondyloarthritis and Joint Symptoms on Health-Related Quality of Life and Fatigue in IBD Patients. Results From a Population-Based Inception Cohort (20-Year Follow-up in the Ibsen Study)
Inflamm. Bowel Dis., 26 (1), 114-124
DOI 10.1093/ibd/izz105
Publications 2019
Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort
Scand. J. Gastroenterol., 54 (1), 41-48
DOI 10.1080/00365521.2018.1548646
Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside
Aliment. Pharmacol. Ther., 50 (4), 397-406
DOI 10.1111/apt.15386
Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis
Liver Int., 39 (2), 371-381
DOI 10.1111/liv.13979
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
J. Intern. Med., 285 (6), 653-669
DOI 10.1111/joim.12880
Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-Grade Dysplasia in Patients With Inflammatory Bowel Disease
Clin. Gastroenterol. Hepatol., 17 (5), 914-+
DOI 10.1016/j.cgh.2018.05.004
Publications 2018
Combining Anti-TNF-alpha and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
Inflamm. Bowel Dis., 24 (5), 997-1004
DOI 10.1093/ibd/izx110
Anemia following Roux-en-Y gastric bypass for morbid obesity; a 5-year follow-up study
Scand. J. Gastroenterol., 53 (8), 917-922
DOI 10.1080/00365521.2018.1489892
Fatigue is not associated with vitamin D deficiency in inflammatory bowel disease patients
World J. Gastroenterol., 24 (29), 3293-3301
DOI 10.3748/wjg.v24.i29.3293
Irritable Bowel-like Symptoms in Ulcerative Colitis are as Common in Patients in Deep Remission as in Inflammation: Results From a Population-based Study [the IBSEN Study]
J. Crohns Colitis, 12 (4), 389-393
DOI 10.1093/ecco-jcc/jjx152
Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population
Scand. J. Gastroenterol., 53 (6), 692-699
DOI 10.1080/00365521.2018.1463391
Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study
Scand. J. Gastroenterol., 53 (3), 273-278
DOI 10.1080/00365521.2018.1424935
Real-life chromoendoscopy for dysplasia surveillance in ulcerative colitis
World J. Gastroenterol., 24 (35), 4069-4076
DOI 10.3748/wjg.v24.i35.4069
Regional differences in anti-TNF- therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study
Scand. J. Gastroenterol., 53 (8), 952-957
DOI 10.1080/00365521.2018.1495258
Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis
Aliment. Pharmacol. Ther., 48 (2), 179-189
DOI 10.1111/apt.14806
Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study
Scand. J. Gastroenterol., 53 (10-11), 1250-1256
DOI 10.1080/00365521.2018.1518482
Ankylosing Spondylitis and Axial Spondyloarthritis in Patients With Long-term Inflammatory Bowel Disease: Results From 20 Years of Follow-up in the IBSEN Study
J. Crohns Colitis, 12 (1), 96-104
DOI 10.1093/ecco-jcc/jjx126
Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries
Gastroenterology, 155 (4), 1079-+
DOI 10.1053/j.gastro.2018.06.043
Development of an index to define overall disease severity in IBD
Gut, 67 (2), 244-254
DOI 10.1136/gutjnl-2016-312648
Publications 2017
Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
Dig. Dis., 35 (1-2), 74-82
DOI 10.1159/000449087
Switching from Remicade (R) to Remsima (R) is well Tolerated and Feasible: A Prospective, Open-label Study
J. Crohns Colitis, 11 (3), 297-304
DOI 10.1093/ecco-jcc/jjw166
Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort-An ECCO-EpiCom Study
J. Crohns Colitis, 11 (10), 1213-1222
DOI 10.1093/ecco-jcc/jjx077
Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population
Scand. J. Gastroenterol., 52 (1), 100-106
DOI 10.1080/00365521.2016.1233577
Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study
J. Crohns Colitis, 11 (5), 571-577
DOI 10.1093/ecco-jcc/jjw193
Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study
Scand. J. Gastroenterol., 52 (3), 351-358
DOI 10.1080/00365521.2016.1256425
Pain may be an important factor to consider in inflammatory bowel disease patients troubled by fatigue
United European Gastroenterol. J., 5 (5), 687-693
DOI 10.1177/2050640616674654
Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis
Gastroenterol. Res. Pract., 2017, 2098293
DOI 10.1155/2017/2098293
The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls
Gut, 66 (4), 611-619
DOI 10.1136/gutjnl-2015-310500
Elevated trimethylamine-N-oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function
United European Gastroenterol. J., 5 (4), 532-541
DOI 10.1177/2050640616663453
Guanylate Cyclase C Activation Shapes the Intestinal Microbiota in Patients with Familial Diarrhea and Increased Susceptibility for Crohn's Disease
Inflamm. Bowel Dis., 23 (10), 1752-1761
DOI 10.1097/MIB.0000000000001264
Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis
J. Hepatol., 66 (6), 1214-1222
DOI 10.1016/j.jhep.2017.01.019
Publications 2016
Fluoride: a risk factor for inflammatory bowel disease?
Scand. J. Gastroenterol., 51 (9), 1019-1024
DOI 10.1080/00365521.2016.1177855
Mortality and Causes of Death in Ulcerative Colitis: Results from 20 Years of Follow-up in the IBSEN Study
Inflamm. Bowel Dis., 22 (1), 141-145
DOI 10.1097/MIB.0000000000000582
Health-related Quality of Life in Patients with Inflammatory Bowel Disease 20 Years After Diagnosis: Results from the IBSEN Study
Inflamm. Bowel Dis., 22 (7), 1679-1687
DOI 10.1097/MIB.0000000000000806
Comparison of the Multiattribute Utility Instruments EQ-5D and SF-6D in a Europe-Wide Population-Based Cohort of Patients with Inflammatory Bowel Disease 10 Years after Diagnosis
Gastroenterol. Res. Pract., 2016, 5023973
DOI 10.1155/2016/5023973
Patients' perceptions of quality of care and follow-up in inflammatory bowel disease
Scand. J. Gastroenterol., 51 (4), 434-441
DOI 10.3109/00365521.2015.1102319
Validity, Reliability, and Responsiveness of the Brief Pain Inventory in Inflammatory Bowel Disease
Can. J. Gastroenterol. Hepatol., 2016, 5624261
DOI 10.1155/2016/5624261
Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation
Mucosal Immunol., 9 (6), 1455-1465
DOI 10.1038/mi.2016.18
Patient-performed extraction of faecal calprotectin
Clin. Chem. Lab. Med., 54 (8), 1357-1363
DOI 10.1515/cclm-2015-1037
Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure
Scand. J. Gastroenterol., 51 (5), 548-555
DOI 10.3109/00365521.2015.1117650
Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease
Gastroenterology, 151 (4), 660-+
DOI 10.1053/j.gastro.2016.06.021
The Use of Complementary and Alternative Medicine among Patients with Inflammatory Bowel Disease Is Associated with Reduced Health-Related Quality of Life
Gastroenterol. Res. Pract., 2016, 6453657
DOI 10.1155/2016/6453657
Publications 2015
Health-related Quality of Life in Inflammatory Bowel Disease in a European-wide Population-based Cohort 10 Years After Diagnosis
Inflamm. Bowel Dis., 21 (2), 337-344
DOI 10.1097/MIB.0000000000000272
Extraintestinal manifestations in Crohn's disease and ulcerative colitis: results from a prospective, population-based European inception cohort
Scand. J. Gastroenterol., 50 (3), 300-305
DOI 10.3109/00365521.2014.991752
Prediction of Endoscopic Disease Activity in Ulcerative Colitis by Two Different Assays for Fecal Calprotectin
J. Crohns Colitis, 9 (2), 164-169
DOI 10.1093/ecco-jcc/jju015
Validation of a new extraction device for measuring faecal calprotectin in inflammatory bowel disease, and comparison to established extraction methods
Scand. J. Clin. Lab. Invest., 75 (5), 355-361
DOI 10.3109/00365513.2015.1030765
Correspondence: fecal calprotectin and cut-off levels in inflammatory bowel disease
Scand. J. Gastroenterol., 50 (9), 1183-1184
DOI 10.3109/00365521.2015.1025830
High faecal calprotectin levels in intestinal tuberculosis are associated with granulomas in intestinal biopsies
Infect. Dis., 47 (3), 137-143
DOI 10.3109/00365548.2014.974206
Challenges in the care of IBD in patients of all ages
Tidsskr. Nor. Laegeforen., 135 (2), 157
DOI 10.4045/tidsskr.14.1267
Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study)
Scand. J. Gastroenterol., 50 (12), 1456-1462
DOI 10.3109/00365521.2015.1064991
Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis
Hepatology, 62 (1), 188-197
DOI 10.1002/hep.27825
Publications 2014
Prevalence of Anemia in Inflammatory Bowel Diseases in European Countries: A Systematic Review and Individual Patient Data Meta-analysis
Inflamm. Bowel Dis., 20 (5), 936-945
DOI 10.1097/01.MIB.0000442728.74340.fd
Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines
Aliment. Pharmacol. Ther., 39 (7), 743-744
DOI 10.1111/apt.12648
Anaemia in inflammatory bowel disease: a population-based 10-year follow-up
Aliment. Pharmacol. Ther., 39 (1), 69-76
DOI 10.1111/apt.12541
Mortality and causes of death in Crohn's disease: results from 20 years of follow-up in the IBSEN study
Gut, 63 (5), 771-775
DOI 10.1136/gutjnl-2013-304766
Thromboembolism in inflammatory bowel disease: results from a prospective, population-based European inception cohort
Scand. J. Gastroenterol., 49 (7), 820-825
DOI 10.3109/00365521.2014.910545
Coexisting Irritable Bowel-Like Symptoms in Inflammatory Bowel Disease in Remission Is Associated With Impaired Social Functioning and Increased Bodily Pain
Gastroenterol. Nurs., 37 (4), 280-287
DOI 10.1097/SGA.0000000000000055
Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: An observational study from Southern India
United European Gastroenterol. J., 2 (5), 397-405
DOI 10.1177/2050640614546947
Routine diagnosis of intestinal tuberculosis and Crohn's disease in Southern India
World J. Gastroenterol., 20 (17), 5017-5024
DOI 10.3748/wjg.v20.i17.5017
Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies
Ann. Gastroenterol., 27 (2), 95-104
What Have We Learnt about the Role of the Environment and Natural Course of IBD in the New Millennium? 20-Year Follow-Up of the IBSEN Cohort
Dig. Dis., 32 1, 2-9
DOI 10.1159/000367818
Fatigue interference with daily living among patients with inflammatory bowel disease
Qual. Life Res., 23 (2), 709-719
DOI 10.1007/s11136-013-0508-4
Sense of Coherence in Patients with Inflammatory Bowel Disease
Gastroenterol. Res. Pract., 2014, 989038
DOI 10.1155/2014/989038
Risk Matrix for Prediction of Advanced Disease in a Population-based Study of Patients with Crohn's Disease (the IBSEN Study)
Inflamm. Bowel Dis., 20 (1), 60-68
DOI 10.1097/01.MIB.0000436956.78220.67
Publications 2013
High burden of iron deficiency and different types of anemia in inflammatory bowel disease outpatients in Scandinavia: A longitudinal 2-year follow-up study
Scand. J. Gastroenterol., 48 (11), 1286-1293
DOI 10.3109/00365521.2013.838605
A Review of Mortality and Surgery in Ulcerative Colitis: Milestones of the Seriousness of the Disease
Inflamm. Bowel Dis., 19 (9), 2001-2010
DOI 10.1097/MIB.0b013e318281f3bb
Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study
Gut, 62 (3), 368-375
DOI 10.1136/gutjnl-2012-302311
Calprotectin Is a Useful Tool in Distinguishing Coexisting Irritable Bowel-Like Symptoms from That of Occult Inflammation among Inflammatory Bowel Disease Patients in Remission
Gastroenterol. Res. Pract., 2013, 620707
DOI 10.1155/2013/620707
Geographical variability and environmental risk factors in inflammatory bowel disease
Gut, 62 (4), 630-649
DOI 10.1136/gutjnl-2012-303661
The management of iron deficiency in inflammatory bowel disease - an online tool developed by the RAND/UCLA appropriateness method
Aliment. Pharmacol. Ther., 38 (9), 1109-1118
DOI 10.1111/apt.12493
Publications 2012
Fatigue in out-patients with inflammatory bowel disease is common and multifactorial
Aliment. Pharmacol. Ther., 35 (1), 133-141
DOI 10.1111/j.1365-2036.2011.04914.x
Hospitalisations and surgery in Crohn's disease
Gut, 61 (4), 622-629
DOI 10.1136/gutjnl-2011-301397
Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: Ten-year results from the IBSEN study
J. Crohns Colitis, 6 (4), 441-453
DOI 10.1016/j.crohns.2011.10.001
Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: Results from the IBSEN study
Inflamm. Bowel Dis., 18 (8), 1540-1549
DOI 10.1002/ibd.21863
Chronic fatigue is associated with increased disease-related worries and concerns in inflammatory bowel disease
World J. Gastroenterol., 18 (5), 445-452
DOI 10.3748/wjg.v18.i5.445
Is patient reported outcome (PRO) affected by different follow-up regimens in inflammatory bowel disease (IBD)? A one year prospective, longitudinal comparison of nurse-led versus conventional follow-up
J. Crohns Colitis, 6 (9), 887-894
DOI 10.1016/j.crohns.2012.01.021
Fatigue and disease-related worries among inflammatory bowel disease patients in remission; is it a reflection of coexisting IBS-like symptoms? A short report
J. Psychosomat. Res., 73 (6), 469-472
DOI 10.1016/j.jpsychores.2012.08.009
Quality of life in patients with inflammatory bowel disease: translation, validity, reliability and sensitivity to change of the Norwegian version of the Short Health Scale (SHS)
Qual. Life Res., 21 (9), 1671-1676
DOI 10.1007/s11136-011-0081-7
Randomised clinical trial: a comparison between a GerdQ-based algorithm and an endoscopy-based approach for the diagnosis and initial treatment of GERD
Aliment. Pharmacol. Ther., 35 (11), 1290-1300
DOI 10.1111/j.1365-2036.2012.05092.x
Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European Collaborative follow-up study (vol 5, pg 430, 2011)
J. Crohns Colitis, 6 (1), 132-133
DOI 10.1016/j.crohns.2011.11.023
Use of complementary and alternative medicine in patients with inflammatory bowel disease: results of a cross-sectional study in Norway
Scand. J. Gastroenterol., 47 (12), 1436-1447
DOI 10.3109/00365521.2012.725092
Complementary and alternative medicine in patients with inflammatory bowel disease: The results of a population-based inception cohort study (IBSEN)
J. Crohns Colitis, 6 (3), 345-353
DOI 10.1016/j.crohns.2011.09.007
Publications 2011
The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia
Scand. J. Gastroenterol., 46 (3), 304-309
DOI 10.3109/00365521.2010.533382
Chronic fatigue is associated with impaired health-related quality of life in inflammatory bowel disease
Aliment. Pharmacol. Ther., 33 (1), 106-114
DOI 10.1111/j.1365-2036.2010.04498.x
Chronic Fatigue Is More Prevalent in Patients with Inflammatory Bowel Disease than in Healthy Controls
Inflamm. Bowel Dis., 17 (7), 1564-1572
DOI 10.1002/ibd.21530
Worries and Concerns among Inflammatory Bowel Disease Patients Followed Prospectively over One Year
Gastroenterol. Res. Pract., 2011, 492034
DOI 10.1155/2011/492034
Measuring health-related quality of life in non-complicated diabetes patients may be an effective parameter to assess patients at risk of a more serious disease course: a cross-sectional study of two diabetes outpatient groups
J. Clin. Nurs., 20 (9-10), 1255-1263
DOI 10.1111/j.1365-2702.2010.03554.x
Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European Collaborative follow-up study
J. Crohns Colitis, 5 (5), 430-442
DOI 10.1016/j.crohns.2011.04.013
Publications 2010
Relationships Between Inflammatory Bowel Disease and Perinatal Factors: Both Maternal and Paternal Disease Are Related to Preterm Birth of Offspring
Inflamm. Bowel Dis., 16 (5), 847-855
DOI 10.1002/ibd.21120
Need for Standardization in Population-Based Quality of Life Studies: A Review of the Current Literature
Inflamm. Bowel Dis., 16 (3), 525-536
DOI 10.1002/ibd.21032
Fecal Calprotectin Variability in Crohn's Disease
Inflamm. Bowel Dis., 16 (7), 1091-1092
DOI 10.1002/ibd.21136
Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis
Aliment. Pharmacol. Ther., 31 (7), 735-744
DOI 10.1111/j.1365-2036.2009.04228.x
Publications 2009
Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population-based cohort followed for ten years
J. Crohns Colitis, 3 (2), 92-99
DOI 10.1016/j.crohns.2008.11.002
Predictive Value of Serologic Markers in a Population-based Norwegian Cohort with Inflammatory Bowel Disease
Inflamm. Bowel Dis., 15 (3), 406-414
DOI 10.1002/ibd.20781
Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)
Scand. J. Gastroenterol., 44 (4), PII 907045459-440
DOI 10.1080/00365520802600961
Publications 2008
C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study
Gut, 57 (11), 1518-1523
DOI 10.1136/gut.2007.146357
Appendectomy and inflammatory bowel disease: The end of a dogma? Reply
Am. J. Gastroenterol., 103 (2), 492
DOI 10.1111/j.1572-0241.2007.01646_12.x
Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years
J. Crohns Colitis, 2 (2), 114-122
DOI 10.1016/j.crohns.2007.10.001
Which Are the 5-ASA Compound Side Effects and How Is It Possible to Avoid Them?
Inflamm. Bowel Dis., 14, S212-S213
DOI 10.1002/ibd.20712
The Association Between Water Supply and Inflammatory Bowel Disease Based on a 1990-1993 Cohort Study in Southeastern Norway
Am. J. Epidemiol., 168 (9), 1065-1072
DOI 10.1093/aje/kwn218
Geographic distribution and ecological studies of inflammatory bowel disease in southeastern Norway in 1990-1993
Inflamm. Bowel Dis., 14 (7), 984-991
DOI 10.1002/ibd.20417
Publications 2007
Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort
Gastroenterology, 133 (2), 412-422
DOI 10.1053/j.gastro.2007.05.051
Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study
Am. J. Gastroenterol., 102 (9), 1955-1963
DOI 10.1111/j.1572-0241.2007.01368.x
Clinical course in Crohn's disease: Results of a five-year population-based follow-up study (the IBSEN study)
Scand. J. Gastroenterol., 42 (5), 602-610
DOI 10.1080/00365520601076124
Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis
Gut, 56 (4), 497-503
DOI 10.1136/gut.2006.101519
Ulcerative colitis: Patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort
Am. J. Gastroenterol., 102 (8), 1692-1701
DOI 10.1111/j.1572-0241.2007.01265.x
Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years
Gastroenterology, 132 (2), 507-515
DOI 10.1053/j.gastro.2006.11.015
Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: Results of a population-based European collaborative follow-up study
Digestion, 75 (2-3), 113-121
DOI 10.1159/000104731
Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab
Inflamm. Bowel Dis., 13 (12), 1584-1586
DOI 10.1002/ibd.20230
Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: A project of the European Collaborative Study Group on Inflammatory Bowel Disease
Inflamm. Bowel Dis., 13 (7), 874-881
DOI 10.1002/ibd.20122
Effect of phenotype on health care costs in Crohn's disease: A European study using the Montreal classification
J. Crohns Colitis, 1 (2), 87-96
DOI 10.1016/j.crohns.2007.08.004
The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients
Inflamm. Bowel Dis., 13 (1), 24-32
DOI 10.1002/ibd.20047
Clinical course in Crohn's disease: Results of a Norwegian population-based ten-year follow-up study
Clin. Gastroenterol. Hepatol., 5 (12), 1430-1438
DOI 10.1016/j.cgh.2007.09.002
Treatment inferred disease severity in Crohn's disease: Evidence for a European gradient of disease course
Scand. J. Gastroenterol., 42 (3), 333-344
DOI 10.1080/00365520600930750
Publications 2006
Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease
Inflamm. Bowel Dis., 12 (5), 402-412
DOI 10.1097/01.MIB.0000218762.61217.4a
Long-term management of patients with symptoms of gastro-oesophageal reflux disease - a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting
Int. J. Clin. Pract., 60 (1), 15-22
DOI 10.1111/j.1368-5031.2006.00768.x
Ulcerative colitis and clinical course: Results of a 5-year population-based follow-up study (The IBSEN study)
Inflamm. Bowel Dis., 12 (7), 543-550
DOI 10.1097/01.MIB.0000225339.91484.fc
Change of diagnosis during the first five years after onset of inflammatory bowel disease: Results of a prospective follow-up study (the IBSEN Study)
Scand. J. Gastroenterol., 41 (9), 1037-1043
DOI 10.1080/00365520600554527
Extreme heterogeneity in CARD15 and DLG5 Crohn disease-associated polymorphisms between German and Norwegian populations
Eur. J. Hum. Genet., 14 (4), 459-468
DOI 10.1038/sj.ejhg.5201576
Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation
Gastroenterology, 131 (3), 719-728
DOI 10.1053/j.gastro.2006.05.052
Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. (vol 131, pg 719, 2006)
Gastroenterology, 131 (6), 2029
Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease
Am. J. Gastroenterol., 101 (7), 1539-1545
DOI 10.1111/j.1572-0241.2006.00602.x
Trondheim gartnerforening 100 år: 1906-2006
[Trondheim gartnerforening], [Trondheim], 147 s.
BIBSYS 061561797
Phenotype at diagnosis predicts recurrence rates in Crohn's disease
Gut, 55 (8), 1124-1130
DOI 10.1136/gut.2005.084061
Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort
Gut, 55 (4), 510-518
DOI 10.1136/gut.2005.072793
Disease outcome of inflammatory bowel disease patients: General outline of a Europe-wide population-based 10-year clinical follow-up study
Scand. J. Gastroenterol., 41 243, 46-54
DOI 10.1080/00365520600664250
Publications 2005
Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: Psychometric assessments and a comparison with general population norms
Inflamm. Bowel Dis., 11 (10), 909-918
DOI 10.1097/01.mib.0000179467.01748.99
Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis
Eur. J. Gastroenterol. Hepatol., 17 (10), 1037-1045
DOI 10.1097/00042737-200510000-00006
A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease
Int. J. Clin. Pract., 59 (6), 665-671
DOI 10.1111/j.1368-5031.2005.00564.x
Six-month management of patients following treatment for gastroesophageal reflux disease symptoms - a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting
Int. J. Clin. Pract., 59 (6), 655-664
DOI 10.1111/j.1368-5031.2005.00563.x
Ulcerative colitis, colorectal cancer and colonoscopic surveillance
Scand. J. Gastroenterol., 40 (8), 881-885
DOI 10.1080/00365520510023701
Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life
J. Rheumatol., 32 (9), 1755-1759
Publications 2004
The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole
Aliment. Pharmacol. Ther., 20 (4), 413-421
DOI 10.1111/j.1365-2036.2004.02085.x
Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis
Scand. J. Gastroenterol., 39 (4), 365-373
DOI 10.1080/00365520310008386
Health-related quality of life in patients with inflammatory bowel disease five years after the inital diagnosis
In Scandinavian journal of gastroenterology, Taylor & Francis, Basingstoke, 39(2004)4, s. 365-73
BIBSYS 051773643
Pediatric inflammatory bowel disease in southeastern Norway: A five-year follow-up study
Digestion, 70 (4), 226-230
DOI 10.1159/000082893
Pediatric inflammatory bowel disease in southeastern Norway: a five year follow-up study
In Digestion, Karger, Basel, 70(2004)4, S. 226-30
BIBSYS 051855887
Publications 2003
Health related quality of life five years after diagnosisin a prospective follow up study of patients with inflammatory bowel disease
In Gut, British Medical Association, London, 52(2003)suppl 6, s.A40
BIBSYS 041729900
Variables influencing health related quality of life in patients with inflammatory bowel disease
In Gastroenterology, Gastroenterology, Baltimore, Md., 124(2003)suppl 1, s.A20 abstrakt S1399
BIBSYS 041729730
Variables influencing health related quality of life (HRQOL) in patients with inflammatory bowel disease (IBD)
In Gastroenterology, Gastroenterology, Baltimore, Md., 124(2003)suppl 1, s.A218 abstrakt S1439
BIBSYS 041729781
Familial occurence of IBD
In Gut, British Medical Association, London, 52(2003)suppl 6, s.A79
BIBSYS 04173467x
Familial occurence og IBD in Ulcerative colitis and Crohn's disease patients and the significance of this for disease behaviour
In Gastroenterology, Gastroenterology, Baltimore, Md., 124(2003)suppl 1, s.A210 abstract S1400
BIBSYS 041734653
Publications 2002
Incidence of inflammatory bowel disease in children in southeastern Norway - A prospective population-based study 1990-94
Scand. J. Gastroenterol., 37 (5), 540-545
DOI 10.1080/00365520252903080
Quality of life in patients with inflammatory bowel disease: translation, data quality, scaling assumptions, validity,reliability and sensitivity to change of the Norwegian version of IBDQ
In Scandinavian journal of gastroenterology, Taylor & Francis, Basingstoke, 37(2002)nr 10, s. 1164-1174
BIBSYS 031388256
Quality of life in patients with inflammatory bowel disease: Translation, data quality, scaling assumptions, validity, reliability and sensitivity to change of the Norwegian version of IBDQ
Scand. J. Gastroenterol., 37 (10), 1164-1174
DOI 10.1080/003655202760373371
Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study
In Lancet, Lancet Ltd., London, 359(2002)nr 9318, s. 1661-1665
BIBSYS 031255922
Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study
Lancet, 359 (9318), 1661-1665
DOI 10.1016/S0140-6736(02)08590-2
On-demand treatment in patients with oesophagitis and reflux symptoms: Comparison of lansoprazole and omeprazole
Scand. J. Gastroenterol., 37 (6), 642-647
DOI 10.1080/00365520212499
Epidemiology of inflammatory bowel disease - methodological considerations
Dig. Liver Dis., 34 (5), 364-369
DOI 10.1016/S1590-8658(02)80131-1
Estimation of Sjogren's syndrome among IBD patients - A six year post-diagnostic prevalence study
Scand. J. Rheumatol., 31 (3), 140-145
Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: A population study (The IBSEN study)
J. Rheumatol., 29 (3), 511-515
Publications 2001
Fibromyalgia and chronic widespread pain in patients with inflammatory bowel disease: A cross sectional population survey
J. Rheumatol., 28 (3), 590-594
The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study)
RHEUMATOLOGY, 40 (11), 1256-1261
DOI 10.1093/rheumatology/40.11.1256
Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months
Aliment. Pharmacol. Ther., 15 (3), 347-354
DOI 10.1046/j.1365-2036.2001.00943.x
Quality of health care in inflammatory bowel disease: Development of a reliable questionnaire (QUOTE-IBD) and first results
Am. J. Gastroenterol., 96 (12), 3329-3336
DOI 10.1016/S0002-9270(01)03896-5
Publications 2000
Chronic inflammatory bowel disease and pregnancy
Scand. J. Gastroenterol., 35 (7), 673-678
DOI 10.1080/003655200750023318
Publications 1999
Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time
Am. J. Gastroenterol., 94 (6), 1564-1569
Publications 1998
Accuracy of IgG serology and other tests in confirming Helicobacter pylori eradication
Scand. J. Gastroenterol., 33 (7), 710-715
Accuracy of seven different tests for the diagnosis of Helicobacter pylori infection and the impact of H-2-receptor antagonists on test results
Scand. J. Gastroenterol., 33 (4), 364-369
Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: Experience from clinical practice in a population with a high frequency of metronidazole resistance
Am. J. Gastroenterol., 93 (2), 212-216
Publications 1997
Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy
Scand. J. Gastroenterol., 32 (12), 1209-1214
DOI 10.3109/00365529709028149
Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: Does in vitro metronidazole resistance have any clinical relevance?
Am. J. Gastroenterol., 92 (2), 248-253
A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: A prospective randomized 1-yr follow-up study
Am. J. Gastroenterol., 92 (4), 653-658
Epidemiology of chronic idiopathic inflammatory bowel disease in south-eastern Norway: a prospective study of the incidence in four counties andrisk factors : The IBSEN study
Department of Internal Medicine, Østfold Central Hospital, Fredrikstad, 1 b. (flere pag.)
BIBSYS 971364230, ISBN 82-7722-069-3
Inflammatory bowel disease: Re-evaluation of the diagnosis in a prospective population based study in south eastern Norway
Gut, 40 (3), 328-332
DOI 10.1136/gut.40.3.328
Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease - Results of a large, prospective population-based study in southeastern Norway, 1990-93
Scand. J. Gastroenterol., 32 (10), 1005-1012
DOI 10.3109/00365529709011217
Publications 1996
Incidence of ulcerative colitis and indeterminate colitis in four counties of southeastern Norway, 1990-93 - A prospective population-based study
Scand. J. Gastroenterol., 31 (4), 362-366
DOI 10.3109/00365529609006411
Incidence of Crohn's disease in four counties in southeastern Norway, 1990-93 - A prospective population-based study
Scand. J. Gastroenterol., 31 (4), 355-361
DOI 10.3109/00365529609006410
Seasonal variations in the onset of ulcerative colitis
Gut, 38 (3), 376-378
DOI 10.1136/gut.38.3.376
Incidence of inflammatory bowel disease across Europe: Is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD)
Gut, 39 (5), 690-697
DOI 10.1136/gut.39.5.690
Publications 1995
INCIDENCE OF INFLAMMATORY BOWEL-DISEASE IN SOUTHEASTERN NORWAY - EVALUATION OF METHODS AFTER 1 YEAR OF REGISTRATION
Digestion, 56 (5), 377-381
DOI 10.1159/000201262
IBD in Norway, with special emphasis on the incidence study of southeastern Norway from 1990, initiated in collaboration with the European Community IBD study group
FALK SYMP, 76, 30-36
Publications 1991
FATAL CYTOMEGALOVIRUS (CMV) COLITIS IN A PATIENT RECEIVING LOW-DOSE PREDNISOLONE THERAPY
Scand. J. Infect. Dis., 23 (4), 495-499
DOI 10.3109/00365549109075099